Renato A Sinico

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6926816/publications.pdf

Version: 2024-02-01

105 papers 8,563 citations

42 h-index 43868 91 g-index

108 all docs 108 docs citations

108 times ranked

5724 citing authors

#	Article	IF	CITATIONS
1	Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. Arthritis and Rheumatology, 2022, 74, 295-306.	2.9	78
2	Clinical and peculiar immunological manifestations of SARS-CoV-2 infection in systemic lupus erythematosus patients. Rheumatology, 2022, 61, 1928-1935.	0.9	15
3	Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature. Autoimmunity Reviews, 2022, 21, 103034.	2.5	8
4	Definition of IgG Subclass-Specific Glycopatterns in Idiopathic Membranous Nephropathy: Aberrant IgG Glycoforms in Blood. International Journal of Molecular Sciences, 2022, 23, 4664.	1.8	7
5	The Impact of Anti-SARS-CoV-2 Vaccine in Patients with Systemic Lupus Erythematosus: A Multicentre Cohort Study. Vaccines, 2022, 10, 663.	2.1	10
6	Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis. Lupus Science and Medicine, 2022, 9, e000689.	1.1	8
7	The Role of Rituximab in Primary Focal Segmental Glomerular Sclerosis of the Adult. Kidney International Reports, 2022, 7, 1878-1886.	0.4	10
8	Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Rheumatology, 2021, 60, 4355-4360.	0.9	21
9	Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part) Tj ETQq1 1	0,784314	4 rgBT /Overh
10	Slowly progressive anti-neutrophil cytoplasmic antibody-associated renal vasculitis: clinico-pathological characterization and outcome. CKJ: Clinical Kidney Journal, 2021, 14, 332-340.	1.4	17
11	Renal involvement in eosinophilic granulomatosis with polyangiitis (EGPA): a multicentric retrospective study of 63 biopsy-proven cases. Rheumatology, 2021, 60, 359-365.	0.9	27
12	Neutrophil Extracellular Traps in the Autoimmunity Context. Frontiers in Medicine, 2021, 8, 614829.	1.2	25
13	Destructuring glomerular diseases with structured deposits: challenges in the precision medicine era. Journal of Nephrology, 2021, 34, 2151-2154.	0.9	2
14	Microarray evaluation of allergen-specific IgE in eosinophilic granulomatosis with polyangiitis. Annals of the Rheumatic Diseases, 2021, 80, 1247-1248.	0.5	2
15	Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome). European Respiratory Journal, 2021, 57, 2004158.	3.1	19
16	MO245OUTCOME OF DIFFERENT INDUCTION REGIMENS IN ANCA-ASSOCIATED GLOMERULONEPHRITIS ACCORDING TO THE HISTOPATHOLOGICAL CHARACTERISTICS: THE REASSESS STUDY*. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
17	Prognostic Factors and Long-Term Outcome with ANCA-Associated Kidney Vasculitis in Childhood. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1043-1051.	2.2	19
18	Second Wave Antibodies in Autoimmune Renal Diseases: The Case of Lupus Nephritis. Journal of the American Society of Nephrology: JASN, 2021, 32, 3020-3023.	3.0	6

#	Article	IF	CITATIONS
19	Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis. Rheumatology, 2021, 60, 3176-3188.	0.9	9
20	Novel Therapies in Takayasu Arteritis. Frontiers in Medicine, 2021, 8, 814075.	1.2	14
21	Neutrophil Extracellular Traps Profiles in Patients with Incident Systemic Lupus Erythematosus and Lupus Nephritis. Journal of Rheumatology, 2020, 47, 377-386.	1.0	77
22	MALDI imaging in Fabry nephropathy: a multicenter study. Journal of Nephrology, 2020, 33, 299-306.	0.9	5
23	Combined Plasmatic and Tissue Approach to Membranous Nephropathy—Proposal of a Diagnostic Algorithm Including Immunogold Labelling: Changing the Paradigm of a Serum-based Approach. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 376-383.	0.6	5
24	P1251THROMBIN GENERATION ASSAY: A POTENTIAL TOOL TO STRATIFY THROMBOTIC RISK IN HEMODIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
25	2020 international consensus on ANCA testing beyond systemic vasculitis. Autoimmunity Reviews, 2020, 19, 102618.	2.5	79
26	P0346THE EFFECTS OF RITUXIMAB MAINTENANCE THERAPY ON LUPUS NEPHRITIS. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
27	PO372RITUXIMAB IN IDIOPATHIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS OF THE ADULT: A MULTICENTRE RETROSPECTIVE SURVEY OF 31 PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	O
28	FCGR3B polymorphism predicts relapse risk in eosinophilic granulomatosis with polyangiitis. Rheumatology, 2020, 59, 3563-3566.	0.9	8
29	P0107DIGITAL PATHOLOGY FOR THE ROUTINE DIAGNOSIS OF RENAL DISEASES: A STANDARD MODEL. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
30	Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis. Annals of the Rheumatic Diseases, 2020, 79, 1077-1083.	0.5	49
31	International Consensus on Antineutrophil Cytoplasm Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1360-1372.	2.5	36
32	Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient). Journal of Nephrology, 2020, 33, 1019-1025.	0.9	26
33	New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group. Internal and Emergency Medicine, 2019, 14, 1193-1197.	1.0	13
34	Anti-Neutrophil Cytoplasmic Antibodies Positivity and Anti-Leukotrienes in Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Monocentric Study on 134 Italian Patients. International Archives of Allergy and Immunology, 2019, 180, 64-71.	0.9	16
35	FP165SLOWLY PROGRESSIVE ANCA-ASSOCIATED GLOMERULONEPHRITIS: A MULTICENTRE STUDY. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	O
36	FP216Renal involvement in EGPA: a multicentre retrospective study of 63 cases. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0

#	Article	IF	Citations
37	Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nature Communications, 2019, 10, 5120.	5.8	160
38	Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients. Arthritis and Rheumatology, 2019, 71, 1670-1680.	2.9	22
39	SAT0239â€PREDICTION OF LONG-TERM EVOLUTIONARY PROFILES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG–STRAUSS) BASED ON BASELINE AND FOLLOW-UP CHARACTERISTICS., 2019, , .		0
40	THU0685â€THE IMPACT OF ACHIEVEMENT OF RESPONSE AT ONE YEAR AFTER STARTING THERAPY ON THE LONG-TERM OUTCOME OF LUPUS NEPHRITIS. , 2019, , .		0
41	MALDI–MSI Pilot Study Highlights Glomerular Deposits of Macrophage Migration Inhibitory Factor as a Possible Indicator of Response to Therapy in Membranous Nephropathy. Proteomics - Clinical Applications, 2019, 13, 1800019.	0.8	10
42	Anticoagulant-related nephropathy: a pathological note. Journal of Thrombosis and Thrombolysis, 2018, 46, 260-263.	1.0	8
43	Routine immunohistochemical staining in membranous nephropathy: in situ detection of phospholipase A2 receptor and thrombospondin type 1 containing 7A domain. Journal of Nephrology, 2018, 31, 543-550.	0.9	14
44	Changing patterns in clinical–histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Annals of the Rheumatic Diseases, 2018, 77, 1318-1325.	0.5	119
45	Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases. Journal of Nephrology, 2018, 31, 271-278.	0.9	50
46	Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. Nephrology Dialysis Transplantation, 2017, 32, gfw251.	0.4	39
47	ANCA-associated vasculitis in childhood: recent advances. Italian Journal of Pediatrics, 2017, 43, 46.	1.0	71
48	Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nature Reviews Rheumatology, 2017, 13, 683-692.	3.5	302
49	Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody–associated vasculitis. Journal of Allergy and Clinical Immunology, 2017, 139, 1684-1687.e10.	1.5	22
50	Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Autoimmunity Reviews, 2017, 16, 1-9.	2.5	140
51	TO037CLINICAL PREDICTORS OF RESPONSE TO RITUXIMAB IN ANCA-ASSOCIATED VASCULITIS: A EUROPEAN COHORT. Nephrology Dialysis Transplantation, 2016, 31, i77-i77.	0.4	1
52	MO040ASSOCIATION OF A TNFSF13B (BAFF) REGULATORY REGION SINGLE NUCLEOTIDE POLYMORPHISMS WITH RESPONSE TO RITUXIMAB IN ANCA-ASSOCIATED VASCULITIS. Nephrology Dialysis Transplantation, 2016, 31, i45-i46.	0.4	0
53	Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg–Strauss). European Respiratory Journal, 2016, 48, 1429-1441.	3.1	102
54	Simultaneous comprehensive multiplex autoantibody analysis for rapidly progressive glomerulonephritis. Medicine (United States), 2016, 95, e5225.	0.4	7

#	Article	IF	Citations
55	Fcî ³ -receptor 3B (FCGR3B) copy number variations in patients with eosinophilic granulomatosis with polyangiitis. Journal of Allergy and Clinical Immunology, 2016, 137, 1597-1599.e8.	1.5	18
56	Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). Autoimmunity Reviews, 2016, 15, 146-154.	2.5	78
57	Eosinophilic Granulomatosis with Polyangiitis (Churg-Straus Syndrome). , 2016, , 129-139.		1
58	The Value of a Panel of Autoantibodies for Predicting the Activity of Lupus Nephritis at Time of Renal Biopsy. Journal of Immunology Research, 2015, 2015, 1-8.	0.9	59
59	Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference. Autoimmunity Reviews, 2015, 14, 692-702.	2.5	63
60	Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. European Journal of Internal Medicine, 2015, 26, 545-553.	1.0	371
61	Systemic vasculitis and pregnancy: A multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies. Autoimmunity Reviews, 2015, 14, 686-691.	2.5	46
62	Value of a commercial kit for detecting anti-C1q autoantibodies and correlation with immunological and clinical activity of lupus nephritis. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1771-7.	1.4	5
63	Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo (2). Journal of the American Society of Nephrology: JASN, 2015, 26, 1905-1924.	3.0	58
64	Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo. Journal of the American Society of Nephrology: JASN, 2014, 25, 2483-2498.	3.0	112
65	Antineutrophil Cytoplasmic Antibodies with Specificity for Proteinase 3., 2014, , 115-120.		1
66	International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Annals of the Rheumatic Diseases, 2014, 73, 17-23.	0.5	471
67	L5. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Presse Medicale, 2013, 42, 507-510.	0.8	28
68	Anti-neutrophil cytoplasmic autoantibodies: Methodological aspects and clinical significance in systemic vasculitis. Autoimmunity Reviews, 2013, 12, 487-495.	2.5	95
69	Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis. Autoimmunity Reviews, 2013, 12, 477-482.	2.5	105
70	Otorhinolaryngological manifestations in granulomatosis with polyangiitis (Wegener's). Autoimmunity Reviews, 2013, 12, 501-505.	2.5	60
71	The kaleidoscopic manifestations of systemic vasculitis. Autoimmunity Reviews, 2013, 12, 459-462.	2.5	5
72	Comparison of PR3-ANCA specific assay performance for the diagnosis of granulomatosis with polyangiitis (Wegener's). Clinical Chemistry and Laboratory Medicine, 2013, 51, 2141-2149.	1.4	11

#	Article	IF	Citations
73	IgG4 immune response in Churg–Strauss syndrome. Annals of the Rheumatic Diseases, 2012, 71, 390-393.	0.5	171
74	PTPN22 R620W polymorphism in the ANCA-associated vasculitides. Rheumatology, 2012, 51, 805-812.	0.9	60
75	Performance evaluation of a novel chemiluminescence assay for detection of anti-GBM antibodies: an international multicenter study. Nephrology Dialysis Transplantation, 2012, 27, 243-252.	0.4	31
76	Antineutrophil cytoplasmic autoantibodies and clinical phenotype in patients with Churg-Strauss syndrome. Journal of Allergy and Clinical Immunology, 2012, 130, 1440.	1.5	12
77	Coexistence of Different Circulating Anti-Podocyte Antibodies in Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1394-1400.	2.2	123
78	Rituximab versus oral cyclophosphamide for treatment of relapses of proliferative lupus nephritis: a clinical observational study. Annals of the Rheumatic Diseases, 2012, 71, 1751-1752.	0.5	25
79	Membranous Nephropathy in Systemic Lupus Erythematosus: Long-Term Outcome and Prognostic Factors of 103 Patients. Seminars in Arthritis and Rheumatism, 2012, 41, 642-651.	1.6	53
80	Detection of anti-IFI16 antibodies by ELISA: clinical and serological associations in systemic sclerosis. Rheumatology, 2011, 50, 674-681.	0.9	23
81	Renal Involvement in Primary Antiphospholipid Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1211-1217.	2.2	83
82	Anti 1q Autoantibodies in Lupus Nephritis. Annals of the New York Academy of Sciences, 2009, 1173, 47-51.	1.8	54
83	Infectious Serologies and Autoantibodies in Wegener's Granulomatosis and Other Vasculitides. Annals of the New York Academy of Sciences, 2009, 1173, 649-657.	1.8	43
84	Churg–Strauss angiitis. Best Practice and Research in Clinical Rheumatology, 2009, 23, 355-366.	1.4	138
85	Complement Cascade in Systemic Lupus Erythematosus. Annals of the New York Academy of Sciences, 2009, 1173, 427-434.	1.8	10
86	Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis. Annals of Internal Medicine, 2009, 150, 670.	2.0	790
87	Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Annals of the Rheumatic Diseases, 2009, 68, 234-237.	0.5	137
88	Antinucleosome antibodies in primary antiphospholipid syndrome: A hint at systemic autoimmunity?. Journal of Autoimmunity, 2008, 30, 51-57.	3.0	50
89	Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe Renal Vasculitis. Journal of the American Society of Nephrology: JASN, 2007, 18, 2180-2188.	3.0	973
90	HLA–DRB4 as a genetic risk factor for Churgâ€6trauss syndrome. Arthritis and Rheumatism, 2007, 56, 3159-3166.	6.7	168

#	Article	IF	CITATIONS
91	A new oligonucleotide-based ELISA for the detection of anti-double-stranded DNA antibodies. Autoimmunity, 2006, 39, 113-119.	1.2	11
92	Renal Involvement in Churg-Strauss Syndrome. American Journal of Kidney Diseases, 2006, 47, 770-779.	2.1	169
93	Anti-glomerular basement membrane antibodies in the diagnosis of Goodpasture syndrome: a comparison of different assays. Nephrology Dialysis Transplantation, 2006, 21, 397-401.	0.4	100
94	Value of a New Automated Fluorescence Immunoassay (EliA) for PR3 and MPO-ANCA in Monitoring Disease Activity in ANCA-Associated Systemic Vasculitis. Annals of the New York Academy of Sciences, 2005, 1050, 185-192.	1.8	28
95	Anti-C1q Autoantibodies in Lupus Nephritis: Prevalence and Clinical Significance. Annals of the New York Academy of Sciences, 2005, 1050, 193-200.	1.8	76
96	Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis and Rheumatism, 2005, 52, 2926-2935.	6.7	592
97	Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: Lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis and Rheumatism, 2004, 50, 3934-3940.	6.7	325
98	Longâ€term renal injury in ANCAâ€associated vasculitis: an analysis of 31 patients with followâ€up biopsies. Nephrology Dialysis Transplantation, 2002, 17, 587-596.	0.4	46
99	Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis and Rheumatism, 2002, 46, 2121-2131.	6.7	849
100	Antiâ€laminin auto antibodies in ANCAâ€associated vasculitis. Nephrology Dialysis Transplantation, 2000, 15, 1600-1603.	0.4	10
101	Renal involvement in primary vasculitides. Clinical Reviews in Allergy and Immunology, 1997, 15, 65-72.	2.9	3
102	High binding of immunoglobulin $M\hat{I}^{0}$ rheumatoid factor from type II cryoglobulins to cellular fibronectin: A mechanism for induction of in situ immune complex glomerulonephritis?. American Journal of Kidney Diseases, 1996, 27, 476-483.	2.1	54
103	HLA-DQ gene polymorphism in primary IgA nephropathy in three European populations. Kidney International, 1996, 49, 477-480.	2.6	40
104	Lack of IgA Antineutrophil Cytoplasmic Antibodies in Henoch-Schönlein Purpura and IgA Nephropathy. Clinical Immunology and Immunopathology, 1994, 73, 19-26.	2.1	32
105	Sneddon's syndrome: clinical and immunohistochemical findings. Clinical Neurology and Neurosurgery, 1994, 96, 310-313.	0.6	7